Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 35

  • 497 clinical trials
  • 182 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Latent autoimmune diabetes in adults

Not recruiting
InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glutamate Decarboxylase 2, Human, Recombinant
  • Sponsor:Norwegian University Of Science And Technolology

Thyroid cancer+18

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Salubris Biotherapeutics Inc.

Neuroblastoma

Not recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dinutuximab Beta
  • Sponsor:Uniwersytet Jagiellonski Collegium Medicum

Diabetic nephropathy

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Hyperinsulinaemic hypoglycaemia+1

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Recordati AG

Medullary thyroid cancer

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Eli Lilly & Co.

Diabetic retinal oedema

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oculis Operations SARL

Adrenogenital syndrome

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Type 2 diabetes mellitus

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Celltrion Inc.

Growth hormone deficiency

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Neuroendocrine tumour+1

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Octreotide
  • Sponsor:Advanced Accelerator Applications

Neoplasm malignant+2

Not recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Selpercatinib
  • Sponsor:Loxo Oncology Inc.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.